التفاصيل البيبلوغرافية
| العنوان: |
Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys |
| المؤلفون: |
Pegu, Amarendra, Xu, Ling, DeMouth, Megan E., Fabozzi, Giulia, March, Kylie, Almasri, Cassandra G., Cully, Michelle D., Wang, Keyun, Yang, Eun Sung, Dias, Joana, Fennessey, Christine M., Hataye, Jason, Wei, Ronnie R., Rao, Ercole, Casazza, Joseph P., Promsote, Wanwisa, Asokan, Mangaiarkarasi, McKee, Krisha, Schmidt, Stephen D., Chen, Xuejun, Liu, Cuiping, Shi, Wei, Geng, Hui, Foulds, Kathryn E., Kao, Shing-Fen, Noe, Amy, Li, Hui, Shaw, George M., Zhou, Tongqing, Petrovas, Constantinos, Todd, John-Paul, Keele, Brandon F., Lifson, Jeffrey D., Doria-Rose, Nicole A., Koup, Richard A., Yang, Zhi-yong, Nabel, Gary J., Mascola, John R. |
| المصدر: |
Cell Reports; January 2022, Vol. 38 Issue: 1 |
| مستخلص: |
Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of escape variants, suggesting a potential benefit of combination bNAb therapy. Here, a trispecific bNAb reduces viremia 100- to 1000-fold in viremic SHIV-infected macaques. After treatment discontinuation, viremia rebounds transiently and returns to low levels, through CD8-mediated immune control. These viruses remain sensitive to the trispecific antibody, despite loss of sensitivity to one of the parental bNAbs. Similarly, the trispecific bNAb suppresses the emergence of resistance in viruses derived from HIV-1-infected subjects, in contrast to parental bNAbs. Trispecific HIV-1 neutralizing antibodies, therefore, mediate potent antiviral activity in vivoand may minimize the potential for immune escape. |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder